Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission

The long-term evolution of COVID-19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID-19 and explored the influence of treatment with system...

Descripción completa

Detalles Bibliográficos
Autores: Catalan, IP, Marti, CR, de la Sota, DP, Alvarez, AC, Gimeno, MJE, Juana, SF, Rodriguez, GH, Bajo, ED, Gaya, NT, Blasco, JU, Rincon, JMR
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p7633
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones7633
Access Level:acceso abierto
Palabra clave:corticosteroids
COVID-19
long COVID
post-acute COVID-19 syndrome
quality of life
SARS-CoV-2
id ES_710d265bfa772c65e557e78226498b4e
oai_identifier_str oai:isabial.fundanetsuite.com:p7633
network_acronym_str ES
network_name_str España
repository_id_str
spelling Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admissionCatalan, IPMarti, CRde la Sota, DPAlvarez, ACGimeno, MJEJuana, SFRodriguez, GHBajo, EDGaya, NTBlasco, JURincon, JMRcorticosteroidsCOVID-19long COVIDpost-acute COVID-19 syndromequality of lifeSARS-CoV-2The long-term evolution of COVID-19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID-19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS-CoV-2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID-19 and to administer the SF-36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF-36 domains for "bodily pain" and "mental health." Corticosteroids administered in the acute phase of COVID-19 could attenuate the presence of long-term symptoms and improve patients' quality of life.John Wiley & Sons Inc.2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones7633Journal of medical virologyISSN: 10969071ISSNe: 01466615reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p76332026-06-12T10:20:37Z
dc.title.none.fl_str_mv Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
title Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
spellingShingle Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
Catalan, IP
corticosteroids
COVID-19
long COVID
post-acute COVID-19 syndrome
quality of life
SARS-CoV-2
title_short Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
title_full Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
title_fullStr Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
title_full_unstemmed Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
title_sort Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission
dc.creator.none.fl_str_mv Catalan, IP
Marti, CR
de la Sota, DP
Alvarez, AC
Gimeno, MJE
Juana, SF
Rodriguez, GH
Bajo, ED
Gaya, NT
Blasco, JU
Rincon, JMR
author Catalan, IP
author_facet Catalan, IP
Marti, CR
de la Sota, DP
Alvarez, AC
Gimeno, MJE
Juana, SF
Rodriguez, GH
Bajo, ED
Gaya, NT
Blasco, JU
Rincon, JMR
author_role author
author2 Marti, CR
de la Sota, DP
Alvarez, AC
Gimeno, MJE
Juana, SF
Rodriguez, GH
Bajo, ED
Gaya, NT
Blasco, JU
Rincon, JMR
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv corticosteroids
COVID-19
long COVID
post-acute COVID-19 syndrome
quality of life
SARS-CoV-2
topic corticosteroids
COVID-19
long COVID
post-acute COVID-19 syndrome
quality of life
SARS-CoV-2
description The long-term evolution of COVID-19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID-19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS-CoV-2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID-19 and to administer the SF-36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF-36 domains for "bodily pain" and "mental health." Corticosteroids administered in the acute phase of COVID-19 could attenuate the presence of long-term symptoms and improve patients' quality of life.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones7633
url https://isabial.portalinvestigacion.com/publicaciones7633
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv John Wiley & Sons Inc.
publisher.none.fl_str_mv John Wiley & Sons Inc.
dc.source.none.fl_str_mv Journal of medical virology
ISSN: 10969071
ISSNe: 01466615
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410624929267712
score 15,81155

Similares en LA Referencia